STUDY Abstract: THU-286 Direct Antiviral Agents are safe and efficacious in pediatric patients with chronic hepatitis C; Real world data from the public health perspective – M. Premkumar, et al.
Study Aims and Results: The study was conducted in India to treat pediatric patients aged 12 to under 18 years old. The children were treatment-naïve and treatment-experienced.
Non-genotyped: 54 children who were treatment-naïve without cirrhosis were not genotyped. The children were treated with sofosbuvir plus daclatasvir for 12 weeks. The cure rate was 100%.
Genotyped: Genotype 1 (9 patients); genotype 3 (22 pts); genotype 4 (2 pts); genotype 5 (1 pt).
Treatment-naïve children with cirrhosis were treated with sofosbuvir plus daclatasvir for 12 weeks. HCV genotype 3 patients with cirrhosis were treated with sofosbuvir plus daclatasvir for 24 weeks and the non-genotype 3 patients were treated with sofosbuvir plus ledipasvir for 24 weeks. Ribavirin was given based on body weight, cirrhosis, prior treatment-experience and duration of treatment. The study period was June 2016 to October 2017.
In the treatment-experienced children with cirrhosis, the cure rate was 97% in the cirrhotic group compared to 100% in the non-cirrhotic group.
There were no serious side effects. The most common side effect was nausea that resolved at the completion of therapy.
Conclusion: Children with hepatitis C can be safely and successfully treated with HCV direct-acting antiviral medications (DAAs).
Editorial Comments: The current study is important for a couple of reasons. The obvious reason is that children can be successfully treated with DAA medications. The second important reason is that children (and adults) living in resource-poor countries who are treatment-naïve without cirrhosis can be treated without being genotyped—an expensive diagnostic test.Share This Page